Trials / Completed
CompletedNCT00141141
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 383 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Atorvastin vs Simvastatin in decreasing LDL-C in diabetic subjects with hypercholesterolemia at the end of the treatment phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | |
| DRUG | Simvastatin |
Timeline
- Start date
- 2004-01-01
- Completion
- 2007-04-01
- First posted
- 2005-09-01
- Last updated
- 2021-02-18
Locations
35 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00141141. Inclusion in this directory is not an endorsement.